The Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel)

Israel Chapter Annual Report 2008

TO:
Board of Directors
International Society for Pharmacoeconomics and Outcomes Research
3100 Princeton Pike, Suite 3E
Lawrenceville, NJ 08648 USA

PREPARED BY:
Dan Greenberg, PhD
Department of Health Systems Management
Faculty of Health Sciences
Ben-Gurion University of the Negev
Beer-Sheva, Israel
Tel: 972-8-647-7421
Fax: 972-8-647-7634
E-mail:dangr@bgu.ac.il

Background:

The Israel Local Chapter was accepted in September 2007. The Chapter has 41 members.

The current Executive Board of the Israel Local Chapter is:

**President**  
Dan Greenberg, PhD  
Department of Health Systems Management  
Faculty of Health Sciences, Ben-Gurion University of the Negev  
Beer-Sheva, Israel

**President-Elect**  
Shmuel Klang, PhD  
Clalit Health Services Headquarters  
Tel-Aviv, Israel

**Secretary**  
Noa Triki, MScPharm (PhD candidate)  
Maccabi Healthcare Services Headquarters  
Tel Aviv Israel

**Treasurer**  
Barak Palatchi, BA  
Pfizer Israel, Herzelia Pituach, Israel
Director  Ariel Hammerman, MScPharm (PhD candidate)
Clalit Health Services Headquarters
Tel-Aviv, Israel

Director  Moshe Leshno, MD, PhD
Tel-Aviv University
Tel-Aviv, Israel

Director  Oren Shavit, MScPharm, PhD
Hebrew University of Jerusalem
Jerusalem, Israel

For more information on the Israel Local Chapter, please visit the ISPOR Local Chapter
http://www.ispor.org/local_chapters/Israel/index.asp.

Enclosure: ISPOR Israel Chapter Annual Report 2008
The 2nd Annual Conference of ISPOR-Israel

The 2nd Annual Conference of ISPOR-Israel was held on September 18-19, 2008 in hotel Dan Panorama in Jerusalem. The 140 conference attendees and speakers included participants from HMOs, academia and research institutes, the Ministry of Health, pharmaceutical and medical device companies and the media. The conference program (in Hebrew and English) can be found at the conference website: http://www.reg.co.il/ispor/index.html, and as an appendix to this document.

The main theme of this year's conference was "The value of anti-cancer drugs". We were honored to host four distinguished speakers from the United Kingdom, United States, and Canada:

Prof. Mike Drummond from the University of York presented the European perspective on the costs and cost-effectiveness of cancer therapies, and the assessment and recommendations of cancer drugs by NICE in the UK. Dr. Chris Pashos, ISPOR 2008-2009 president, presented the methods for assessment of Health-related Quality of Life in Cancer. Dr. Vardit Ravitsky, Senior Ethics Policy Advisor, Canadian Institutes of Health Research addressed the considerations for reimbursement approval of new anti-cancer drugs in Canada, and Dr. Mel Walker, Director of Global Health Outcomes, Oncology for GlaxoSmithKline discussed the industry perspective on the pricing and reimbursement of anti-cancer drugs.

The Annual Meeting of ISPOR-Israel Members' Assembly

According to its constitution, ISPOR-Israel held its annual meeting of the members' assembly on September 18, 2008. During this meeting, we discussed ideas to promote the field of pharmacoeconomics and outcomes research in Israel and to enhance the involvement of health practitioners in ISPOR-Israel activities. The annual financial report was presented and approved. The executive committee officers were re-elected for a term of one year. The assembly also elected an audit committee of two ISPOR-Israel members

Media Coverage and Report on ISPOR-Israel Activities

Dr. Orna Tal, an ISPOR-Israel member authored an article summarizing reflections from ISPOR-Israel first Annual Conference. The paper has been published in the May 2008 issue of “Harefuah”, the Journal of the Israel Medical Association (in Hebrew). The journal is distributed to the vast majority of physicians practicing in Israel.
The 2\textsuperscript{nd} Annual Conference of \textbf{ISPOR-Israel} and the meeting deliberation were covered by Ronny Linder-Gantz, a health journalist for "TheMarker", one of the largest daily economic newspapers in Israel. Two of the published articles are attached as an appendix to this report.

An interview with Dr. Dan Greenberg on \textbf{ISPOR-Israel} mission and activities appeared in the September-October 2008 issue of "The Pharma", a bi-monthly journal distributed to pharmacists and family physicians in Israel

\textbf{2009 Upcoming Activities}

The 3\textsuperscript{rd} Annual Meeting of ISPOR-Israel is planned for September-October 2009. Additional activities planned are: a one day conference on issues relating to co-payment for pharmaceuticals and methods to improve adherence to treatment.

ISPOR-Israel members are planning to present their scientific work at the ISPOR 14\textsuperscript{th} Annual International Meeting and the ISPOR 12\textsuperscript{th} Annul European Congress.
Appendix to the 2008 Annual Report

Abbreviated Program of the ISPOR-Israel 2nd Annual Meeting

Thursday, September 18, 2008
08:30 - 09:30  Registration
09:30 - 09:45  Welcome & Introduction
               Prof. Joshua Shemer
               Prof. Joseph Pilsik
               Dr. Boaz Lev
09:45 - 10:00  Welcome from ISPOR
               Dr. Chris L. Pashos, 2008-2009 ISPOR President
10:00 - 11:00  A European perspective on the costs and cost-effectiveness of cancer therapies
               Prof. Mike Drummond, University of York
11:00 - 11:30  Coffee Break

SESSION I
11:30 - 13:00  Reimbursement of anti-cancer drugs.
               Chair: Prof. Joshua Shemer
11:30 - 12:15  Pricing and reimbursement of anti-cancer drugs: the industry perspective
               Dr. Mel Walker, Director, Global Health Outcomes, Oncology, GlaxoSmithKline.
12:15 - 13:00  Considerations for reimbursement approval of new anti-cancer drugs - the Canadian experience
               Dr. Vardit Ravitsky, Senior Ethics Policy Advisor, Canadian Institutes of Health Research
13:00 - 14:00  Lunch Break

SESSION II
14:00 - 16:45  Physicians’ and patients’ perspective of anti-cancer drugs cost & effectiveness.
               Chair: Prof. Adi Shani
14:00 - 14:30  Oncologists priorities for improving the cancer treatment system
               Dr. David Chinitz
14:30 - 15:00  Do patients understand the true costs, risks & benefits of cancer treatment?
               Mrs. Eti Samama
               Mr. Meidad Gissin
15:00 - 16:15  Issue Panel I:
               Should patients have access to effective cancer care regardless of cost?
               Chair: Prof. Gabi Ben-Nun
               Dr. Ehud Kukia
               Prof. Noam Zohar
               Rabbi Yuval Cherlow
               Prof. Baruch Klein
               Mr. David Goren
               Mrs. Miri Ziv
16:15 - 16:45  Coffee Break
SESSION III

16:45 - 18:00 Contributed Podium Presentations - Session I
Chairs: Dr. Amir Shmueli & Dr. Segev Shani

16:45 - 17:00 Expenditure on Anti-Cancer Drugs Compared to Other Drugs in the Past Decade.

17:00 - 17:15 The Cost and Feasibility of a Prostate Cancer Early Detection Program in Gastroenterology Units: The Experience of the Hadassah Ein-Kerem Medical Center
Shafran-Tikva S1, Lysy Y1, Goldin E1, Greenberg D2 1Gastroenterology Unit, Hadassah University Medical Center Ein Kerem, Jerusalem; 2Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva.

17:15 - 17:30 The Impact of Oncotype Dx® Assay Use on Real Life Treatment Decisions in N-, ER+ Early-Stage Breast Cancer Patients: Its Implications for Budget Impact Analysis.
Hammerman A1, Klang SH1, Liebermann N1, Merling S1 Efrat N2 1Clalit Health Services Headquarters, Tel-Aviv; 2Kaplan Medical Center, Rehovot.

17:30 - 17:45 Cost Effectiveness of Treating Colorectal Cancer With Cetuximab As a 3rd Line Therapy Using K-Ras Mutation Status as an Inclusion Criteria

17:45 - 18:00 Economic Evaluation of Fulvestrant (Faslodex®) As an Additional Endocrine Step in the Treatment Sequence For Hormone-Receptor Positive Advanced and Metastatic Breast Cancer In Israel
Greenberg D1, Rabinovich M1, Hirsch M1 1Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva; 2AstraZeneca (Israel) Ltd., Ṛa‘ānana; 3AstraZeneca Pharmaceutical Ltd.

19:00 Dinner & Evening tour of Jerusalem
Friday, September 19, 2008

SESSION IV

08:30 - 11:10 Chair: Prof. Avi Porath

08:30 - 09:10 Assessment and recommendations of cancer drugs by NICE in the UK
   Prof. Mike Drummond, University of York

09:10 - 09:50 Assessment of Health-related Quality of Life in Cancer
   Dr. Chris L. Pashos, 2008–2009 ISPOR President

09:50 - 11:00 Issue Panel II:
   Physicians' recommendations for non-reimbursed therapies: Is the Israeli
   Law of Patients Rights an ethical obstacle for the treating oncologist?
   Chair: Prof. Alik Aviram
   Prof. Rafi Catane
   Dr. Bella Kaufman
   Dr. Nicky Liebermann
   Dr. Shai Feuerling
   Dr. Udi Kantor

11:00 - 11:20 Coffee Break

SESSION V

11:20 - 12:50 Contributed Podium Presentations - Session II
   Chairs: Dr. Moshe Leshno & Dr. Yossi Lomnicki

11:20 - 11:35 Clinical & Economical Impact of a Centralized Pre-Authorization Mechanism
   for Erythropoietin

11:35 - 11:50 Cost-Effectiveness Analysis of a Drug-Drug Interactions Alert System
   Appleboim R1, Hammerman A2, Klamb SH2, Leshno M1 1The Faculty of Management, Tel Aviv University. 2Clalit Health Services Headquarters, Tel-Aviv

11:50 - 12:05 A Cost Effectiveness Analysis of Botulinum Toxin A (Dysport) For the
   Treatment of Upper Arm Spasticity In Post Stroke Patients
   Leshno M, Tel-Aviv University, Tel-Aviv

12:05 - 12:20 Cost Effectiveness of Secondary Prevention of Stroke In Israel Using
   Dipyridamole+Aspirin In Comparison With Aspirin Only

12:20 - 12:35 Cost Utility Analysis of Vaccination Against HPV In Israel
   Ginsberg GM1, Fisher M1, Ben-Shahar P, Bornstein J, 1Medical Technology Assessment Sector, Ministry of Health, Jerusalem. 2Clalit Health Services, Nahariya 3Department of Gynecology, Hadassah Medical Center, Mount-Skopos, Jerusalem 4Department of Obstetrics and Gynecology, Western Galilee Hospital, Nahariya, and Rappaport Faculty of Medicine, Technion, Haifa, Israel

12:35 - 12:50 Treating Patients with Microsatellite Instable Colorectal Tumors - the
   Economic Point of View.
   Rennert G1, Regev S2, 1Carmel Medical Center, Haifa 2Planning and Health Policy Division, Clalit Health Services Headquarters, Tel-Aviv

   Dr. Shimuel Klang, Dr. Dan Greenberg

13:30 - 14:30 Lunch